NEWS

• Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer’s Disease Prognostic Technology
  Milan, Italy and Secaucus, NJ — October 25, 2023 – Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer’s disease (AD), today announced that it has formed a strategic collaboration with Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, designed to improve access to high quality blood tests for evaluating the risk of Alzheimer’s disease.
• Diadem Presents Data at 2023 AAIC® Showing its AlzoSure® Blood Test Can Identify Patients at High Risk of Cognitive Decline due to Alzheimer’s Disease
  Milan, Italy and Amsterdam, Netherlands, July 19, 2023
  Diadem srl, a company developing the first blood-based test for the early prediction of clinical progression to Alzheimer’s disease (AD), today announced that study data being presented at the Alzheimer’s Association International Conference^® 2023 (AAIC^®) further strengthens the evidence supporting the prognostic value of Diadem’s AlzoSure^®Predict blood-based biomarker test, which can accurately identify whether or not individuals over the age of 50 will experience a significant cognitive decline due to AD years before the full onset of symptoms. The study data are included in a scientific poster that is being presented today at AAIC^®2023.

• Diadem Reports New Data Showing Its AlzoSure® Predict Blood Test Can Accurately Identify “Rapid Progressors” Who Will Develop Alzheimer’s Disease Within Two Years
  Milan, Italy and San Francisco, California, January 9, 2023 
  DiademSpA,acompany developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD),today announced that its researchers have developed computational methods that enable its AlzoSure® Predict prognostic technology toaccuratelyidentify individuals who will rapidly progress to AD within twoyears’ time.More than95%of the patients above thenew computational “cutoff”used to define“rapidprogressors”were shown toprogress to AD within two years’ time, regardless of their baseline diagnosis.

• At CTAD 2022 Diadem highlights how its Alzosure® Predict Prognostic Blood Test for Alzheimer’s Disease will Help Patients and Facilitate Development of New Therapies
  Milan, ITALY and San Francisco, USA – December 5th, 2022
  Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), presented clinical data at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference highlighting the accuracy and clinical utility of its AlzoSure® Predict prognostic blood test for Alzheimer’s Disease (AD), setting the stage for commercialization in the U.S. beginning in 2023.

• Diadem builds out executive team as it prepares for commercialisation of its Alzosure Predict® Prognostic Test for Alzheimer’s Disease
  Milan, ITALY – November 21, 2022
  Diadem SpA, (or Diadem US, Inc.) a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced key additions to its senior management team.

• Diadem Partners with Dementias Platform UK to Advance Diagnosis and Treatment of Alzheimer’s Disease
  Milan, ITALY – May xx, 2022
  Diadem SpA, a company developing AlzoSure® Predict, the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced ….

• Diadem Announces Publication of Clinical Study Confirming Its AlzoSure® Predict Blood Test Can Accurately Predict Progression to Alzheimer’s Disease Six Years Before Diagnosis
  Milan, ITALY – May 16, 2022
  Diadem SpA today announced publication of the results of a clinical validation study of its AlzoSure® Predict prognostic blood test for Alzheimer’s disease (AD) ….

• Diadem Announces Publication of Peer-Reviewed Article Describing How Post-Translational Modifications of p53 Variants May Contribute to Development of Alzheimer’s Disease
  Milan, ITALY – April 28, 2022
  Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced …

• Diadem Announces First Closing of €10 Million Equity Financing for Its AlzoSure® Predict Prognostic Blood Test for Alzheimer’s Disease
  Milan, Italy, March 28, 2022
  Diadem SpA, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the closing of the first tranche ….

• Diadem Presents Data at AD/PD™ 2022 International Conference Demonstrating Its New AlzoSure® Confirm Blood Test Has the Potential to Accurately Diagnose Alzheimer’s Disease
  Milan, ITALY and Barcelona, SPAIN – March 22, 2022
  Diadem srl, a company developing blood-based tests for the early prediction and diagnosis of Alzheimer’s disease (AD), today announced that …

• European Investment Bank to Provide a €7.5 Million Loan to Support Further Research and Development of Diadem’s AlzoSure® Predict Blood Test for Alzheimer’s Disease
  Luxembourg City (Luxembourg) and Brescia (Italy) – March 07, 2022
  The European Investment Bank (EIB) has awarded a €7.5 million loan to Diadem Srl, a company developing the first blood-based prognostic test for the early prediction of Alzheimer’s disease …

• Diadem Receives CE-IVD Certification to Market Its AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer’s Disease in Europe
  Brescia, Italy – February 28, 2022
  Diadem Srl today announced CE IVD certification for its AlzoSure® Predict prognostic blood test for the early prediction of Alzheimer’s disease …

• FDA Grants Breakthrough Device Designation to Diadem’s AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer’s Disease
  San Francisco, CA – January 18, 2022
  Diadem U.S., Inc.,(a subsidiary of Diadem Srl) a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced …

• Presentation at Clinical Trials on Alzheimer’s Disease Meeting Highlights How Diadem’s AlzoSure® Predict Can Enable AD Clinical Trials and Screening for Early Detection of AD
  Milan, ITALY and Boston, MA, USA – November 15, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that it presented …

• Diadem Presents Data at 22nd International Conference on Alzheimer’s Drug Discovery Highlighting Its Blood-Based Biomarker Test Is 84% Concordant with Amyloid Brain Imaging
  Milan, ITALY – October 6, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease, today announced release …

• Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer’s Disease
  Milan, ITALY – September 23, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced release …

• Diadem Announces Publication of Clinical Data Showing Its AlzoSure® Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease Six Years Before Diagnosis
  Milan, ITALY – August 26, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced results …

• Diadem Awarded Patent in China for Its AlzoSure® Prognostic Biomarker Technology that Accurately Predicts Progression to Alzheimer’s Disease
  Milan, ITALY – August 4, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced that its AlzoSure® prognostic…

• Diadem Presents Clinical Validation Interim Data Confirming Its AlzoSure® Prognostic Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease
  Milan, ITALY – May 18, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today …

• Diadem Presents New Data at AAIC® Symposium Showing Its Blood-Based Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease 7 Years Before Symptoms Occur
  Milan, ITALY – May 13, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today …

• New Scientific Publications Show Diadem’s Blood-Based AlzoSure® Biomarker Test Can Predict Which Patients Will Progress to Alzheimer’s Disease Years Before Symptoms Occur
  Milan, ITALY – February 01, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the publication…

• Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer’s Disease International Conference
  Milan, ITALY – December 11, 2020
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that it hosted a Symposium on its prognostic biomarker…

• Diadem Names Dr. Tamas Bartfai Chair of Its Medical Advisory Board
  Milan, ITALY – December 1, 2020
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced that noted neuroscientist and Alzheimer’s disease…

• Development of Blood-Based Alzheimer’s Prognostic Propels Diadem to Finalist Status for Both the Gaetano Marzotto Company Prize and 2030 Social Impact Special Prize
  Milan, ITALY – November 16, 2020
  pool of 600 applicants. The companies were analyzed by experts representing relevant public, private, financial, technological and specialist…

• Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO
  Milan, ITALY – October 19, 2020
  Diadem srl, a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that Paul Kinnon has been named…